Lundbeckfonden BioCapital
We are an evergreen venture capital fund that invests in life science companies, supporting the translation and commercialisation of ground-breaking science.
Our Ambition
To identify scientific breakthroughs and develop new, ground-breaking medical solutions with a special focus on novel medicines, in the process generating an attractive financial return while supporting the growth of the Danish biotech ecosystem including by building long term sustainable businesses.
News About Us
-
Vesper Bio
Vesper Bio, backed by Lundbeckfonden BioCapital, initiates a Phase I study to evaluate its lead asset VES001, for the treatment of FTD (GRN mutation), addressing a critical unmet medical need
-
Press Release
A syndicate consisting of the Lundbeck Foundation BioCapital, EIR Ventures, EIFO and UCPH Ventures has just made their first investment in the Danish biotech company Dania Therapeutics (Dania Tx).
-
Press Release
Lundbeckfonden BioCapital and +ND Capital have invested in the Danish biotech company Notify Therapeutics which emerged from Professor Karin Lykke-Hartmann’s research into female infertility.
Investment Team
-
Managing Partner Lundbeckfonden BioCapital
-
Operating Partner
-
Partner
-
Senior Principal
-
Principal
-
Associate
-
Associate
-
Executive Assistant & Facility Manager